T. Rowe Price (CYTK holder) discloses 14.5% Cytokinetics ownership in 13G/A

Rhea-AI Filing Summary

T. Rowe Price Investment Management, Inc. filed an amended Schedule 13G reporting a significant ownership position in Cytokinetics, Inc. common stock as of 12/31/2025.

The firm reports beneficial ownership of 17,716,372 shares, representing 14.5% of the outstanding common stock. It has sole voting power over 17,330,683 shares and sole dispositive power over 17,700,030 shares, with no shared voting or dispositive power.

T. Rowe Price states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Cytokinetics, and it expressly denies being the beneficial owner of the securities beyond what is required for reporting.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 3)

CYTOKINETICS INC

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

23282W605

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 23282W605

1

Names of Reporting Persons

T. Rowe Price Investment Management, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

MARYLAND

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 17,330,683.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 17,700,030.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

17,716,372.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

14.5 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: CYTOKINETICS INC
(b)	Address of issuer's principal executive offices: 350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA, 94080
Item 2.
(a)	Name of person filing: T. Rowe Price Investment Management, Inc.
(b)	Address or principal business office or, if none, residence: 1307 Point Street, Baltimore, MD 21231
(c)	Citizenship: Maryland
(d)	Title of class of securities: COMMON STOCK
(e)	CUSIP No.: 23282W605
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 17716372
(b)	Percent of class: 14.5 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 17330683
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 17700030
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. T. Rowe Price Investment Management, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Investment Management is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

T. Rowe Price Investment Management, Inc.

Signature:	Ellen York
Name/Title:	Vice President
Date:	02/17/2026

FAQ

What ownership stake in Cytokinetics (CYTK) does T. Rowe Price report?

T. Rowe Price Investment Management reports beneficial ownership of 17,716,372 Cytokinetics common shares, representing 14.5% of the class. This sizeable position makes it a significant institutional holder under beneficial ownership rules.

What voting and dispositive power does T. Rowe Price have over CYTK shares?

T. Rowe Price reports sole voting power over 17,330,683 Cytokinetics shares and sole dispositive power over 17,700,030 shares, with no shared voting or dispositive power reported for this position.

As of what date is T. Rowe Price’s Cytokinetics ownership reported?

The ownership figures are reported as of 12/31/2025, which is identified as the date of the event requiring this Schedule 13G/A filing. All share and percentage data in the statement are anchored to that date.

Does T. Rowe Price intend to influence control of Cytokinetics (CYTK)?

T. Rowe Price certifies that the Cytokinetics securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the company, consistent with passive investment intent.

What type of SEC filing is this for Cytokinetics (CYTK)?

This is an amended Schedule 13G/A, which reports the beneficial ownership of Cytokinetics common stock by a large institutional investor. Amendment No. 3 updates previously reported ownership information for T. Rowe Price Investment Management, Inc.

Where is T. Rowe Price Investment Management, Inc. organized and based?

T. Rowe Price Investment Management, Inc. is organized under the laws of Maryland, with its principal business office at 1307 Point Street, Baltimore, MD 21231, as disclosed in the ownership statement.